What Is The Price Target For Fate Therapeutics Fate Stock Fate Q4 2025 Earnings Fate Therapeutics Inc. Posts Narrow Eps Beat No Revenue Reported 20260410 1 TransCode Therapeutics RNAZ Q4 2024 Results Miss Estimates EPS 15064 vs 9168 Short Sellers Identify Opportunities Amid AIDriven Market Hype Collective Mining CNL Sees Major Price Target Upgrade as Exploration Potential Strengthens Core Inflation Hits 32 as FirstQuarter Growth Slows Amid Iran Conflict Fiverr FVRR Holds Steady Near Key Support as Stock Trades Flat Yum Brands YUM Climbs 08 as Investors Digest Market Trends Key Levels to Watch Vertiv Holdings VRT Reaches 32746 After Modest Gain Nears Key Resistance Level XTI Aerospace Inc XTIA Surges 7 as Shares Test Key Resistance Level